CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor α in Active Crohn's Disease.


Journal

Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676

Informations de publication

Date de publication:
25 Jul 2019
Historique:
pubmed: 5 2 2019
medline: 25 1 2020
entrez: 5 2 2019
Statut: ppublish

Résumé

Tumour necrosis factor [TNF]α- and IL-17A-producing T cells are implicated in Crohn's disease [CD]. Tissue-resident memory T [TRM] cells are tissue-restricted T cells that are regulated by PR zinc finger domain 1 [PRDM1], which has been implicated in pathogenic Th17 cell responses. TRM cells provide host defence but their role in CD is unknown. We thus examined CD4+ TRM cells in CD. Colon samples were prospectively collected at endoscopy or surgery in CD and control subjects. Flow cytometry and ex vivo assays were performed to characterise CD4+ TRM cells. CD4+ TRM cells are the most abundant memory T cell population and are the major T cell source of mucosal TNFα in CD. CD4+ TRM cells are expanded in CD and more avidly produce IL-17A and TNFα relative to control cells. There was a unique population of TNFα+IL-17A+ CD4+ TRM cells in CD which are largely absent in controls. PRDM1 was highly expressed by CD4+ TRM cells but not by other effector T cells. Suppression of PRDM1 was associated with impaired induction of IL17A and TNFA by CD4+ TRM cells. CD4+ TRM cells are expanded in CD and are a major source of TNFα, suggesting that they are important in CD. PRDM1 is expressed by TRM cells and may regulate their function. Collectively, this argues for prospective studies tracking CD4+ TRM cells over the disease course.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Tumour necrosis factor [TNF]α- and IL-17A-producing T cells are implicated in Crohn's disease [CD]. Tissue-resident memory T [TRM] cells are tissue-restricted T cells that are regulated by PR zinc finger domain 1 [PRDM1], which has been implicated in pathogenic Th17 cell responses. TRM cells provide host defence but their role in CD is unknown. We thus examined CD4+ TRM cells in CD.
METHODS METHODS
Colon samples were prospectively collected at endoscopy or surgery in CD and control subjects. Flow cytometry and ex vivo assays were performed to characterise CD4+ TRM cells.
RESULTS RESULTS
CD4+ TRM cells are the most abundant memory T cell population and are the major T cell source of mucosal TNFα in CD. CD4+ TRM cells are expanded in CD and more avidly produce IL-17A and TNFα relative to control cells. There was a unique population of TNFα+IL-17A+ CD4+ TRM cells in CD which are largely absent in controls. PRDM1 was highly expressed by CD4+ TRM cells but not by other effector T cells. Suppression of PRDM1 was associated with impaired induction of IL17A and TNFA by CD4+ TRM cells.
CONCLUSIONS CONCLUSIONS
CD4+ TRM cells are expanded in CD and are a major source of TNFα, suggesting that they are important in CD. PRDM1 is expressed by TRM cells and may regulate their function. Collectively, this argues for prospective studies tracking CD4+ TRM cells over the disease course.

Identifiants

pubmed: 30715262
pii: 5306188
doi: 10.1093/ecco-jcc/jjz010
pmc: PMC6939878
doi:

Substances chimiques

IL17A protein, human 0
Interleukin-17 0
Tumor Necrosis Factor-alpha 0
PRDM1 protein, human 138415-26-6
Positive Regulatory Domain I-Binding Factor 1 EC 2.1.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

905-915

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK034933
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK108901
Pays : United States

Informations de copyright

Copyright © 2019 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Références

Immunity. 2016 Jan 19;44(1):131-142
pubmed: 26750311
Nature. 2012 Nov 1;491(7422):119-24
pubmed: 23128233
Front Immunol. 2017 Aug 28;8:1036
pubmed: 28894447
Mucosal Immunol. 2017 Mar;10(2):520-530
pubmed: 27461178
Science. 2016 Apr 22;352(6284):459-63
pubmed: 27102484
Nat Rev Immunol. 2016 Feb;16(2):79-89
pubmed: 26688350
Gastroenterology. 2017 Nov;153(5):1320-1337.e16
pubmed: 28782508
Gastroenterology. 2011 Dec;141(6):2026-38
pubmed: 21875498
Trends Immunol. 2013 Jan;34(1):27-32
pubmed: 23036434
Immunity. 2014 Dec 18;41(6):886-97
pubmed: 25526304
Immunity. 2013 Jan 24;38(1):187-97
pubmed: 23260195
Cell Rep. 2015 Jun 23;11(11):1822-33
pubmed: 26074076
Nat Commun. 2018 Apr 10;9(1):1366
pubmed: 29636450
Sci Rep. 2016 Feb 10;6:20686
pubmed: 26861911
Immunity. 2013 Oct 17;39(4):687-96
pubmed: 24076049
Scand J Gastroenterol. 2013 Mar;48(3):311-9
pubmed: 23302000
Cell Rep. 2017 Sep 19;20(12):2921-2934
pubmed: 28930685
N Engl J Med. 2016 Nov 17;375(20):1946-1960
pubmed: 27959607
J Exp Med. 2017 Oct 2;214(10):2915-2932
pubmed: 28855242
J Crohns Colitis. 2016 Aug;10(8):989-97
pubmed: 26896086
J Immunol. 2014 Dec 15;193(12):5933-50
pubmed: 25392531
Immunity. 2015 Oct 20;43(4):727-38
pubmed: 26431948
Nat Rev Immunol. 2014 May;14(5):329-42
pubmed: 24751956
Gastroenterology. 2017 Feb;152(2):374-388.e4
pubmed: 27780712
Science. 2014 Oct 3;346(6205):93-8
pubmed: 25170048
Clin Exp Immunol. 1993 Oct;94(1):174-81
pubmed: 8403503
Nature. 2006 Mar 23;440(7083):540-4
pubmed: 16525420
Cell. 2014 Nov 6;159(4):814-28
pubmed: 25417158
J Crohns Colitis. 2010 Oct;4(4):355-66
pubmed: 21122530
Immunity. 2015 Oct 20;43(4):739-50
pubmed: 26431947
Trends Immunol. 2015 Jan;36(1):3-12
pubmed: 25248463
Gut. 2003 Jan;52(1):65-70
pubmed: 12477762
Nat Rev Immunol. 2012 Feb 17;12(3):191-200
pubmed: 22343568
Gastroenterology. 2016 Sep;151(3):489-500.e3
pubmed: 27267052
Nat Immunol. 2013 Dec;14(12):1294-301
pubmed: 24162776
Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):7061-6
pubmed: 26038559
Gut. 1997 Apr;40(4):443-8
pubmed: 9176068
Gut. 1993 Dec;34(12):1705-9
pubmed: 8031350
J Exp Med. 2015 Aug 24;212(9):1405-14
pubmed: 26216123
J Immunol. 2005 Nov 15;175(10):6900-8
pubmed: 16272349
Nat Rev Gastroenterol Hepatol. 2017 May;14(5):269-278
pubmed: 28144028
Gut. 2012 Dec;61(12):1693-700
pubmed: 22595313
Blood. 2008 Apr 1;111(7):3867-71
pubmed: 18235046
Gastroenterol Hepatol (N Y). 2010 Sep;6(9):587-96
pubmed: 21088749
Immunity. 2016 May 17;44(5):1227-39
pubmed: 27178470
J Immunol. 2000 Apr 1;164(7):3608-15
pubmed: 10725717
Nat Immunol. 2011 Jun;12(6):560-7
pubmed: 21516112
Annu Rev Immunol. 2004;22:745-63
pubmed: 15032595
Gut. 2015 Feb;64(2):233-42
pubmed: 24700437
Science. 2006 Dec 1;314(5804):1461-3
pubmed: 17068223

Auteurs

Shrinivas Bishu (S)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.

Mohammed El Zaatari (M)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.
University of Michigan Crohn's and Colitis Program, University of Michigan, AnnArbor, MI, USA.

Atsushi Hayashi (A)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.
Tokyo R&D Center, Miyarisan Pharmaceutical, Tokyo, Japan.

Guoqing Hou (G)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.

Nicole Bowers (N)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.

Jami Kinnucan (J)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.
University of Michigan Crohn's and Colitis Program, University of Michigan, AnnArbor, MI, USA.

Beth Manoogian (B)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.
University of Michigan Crohn's and Colitis Program, University of Michigan, AnnArbor, MI, USA.

Michelle Muza-Moons (M)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.
University of Michigan Crohn's and Colitis Program, University of Michigan, AnnArbor, MI, USA.

Min Zhang (M)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.

Helmut Grasberger (H)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.

Charlie Bourque (C)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.

Weiping Zou (W)

Department of Surgery, University of Michigan, AnnArbor, MI, USA.

Peter D R Higgins (PDR)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.
University of Michigan Crohn's and Colitis Program, University of Michigan, AnnArbor, MI, USA.

Jason R Spence (JR)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.
Department of Cell and Developmental Biology, University of Michigan, AnnArbor, MI, US.

Ryan W Stidham (RW)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.
University of Michigan Crohn's and Colitis Program, University of Michigan, AnnArbor, MI, USA.

Nobuhiko Kamada (N)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.

John Y Kao (JY)

Division of Gastroenterology, Department of Medicine, University of Michigan, AnnArbor, MI, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH